We performed a prospective cohort study to investigate oseltamivir administration in critically ill children. We found that enteric tube administration of oseltamivir resulted in lower concentrations of its active metabolite compared with oral delivery. These findings could have significant clinical implications, and more studies are required to better understand the effects of administration route on potential lower systemic metabolite exposure.
From the *Division of Hospital Medicine, Department of Pediatrics
†Division of Clinical Pharmacology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
‡Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
§Division of Critical Care Medicine, Department of Pediatrics. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Accepted for publication August 20, 2019.
Supported by funding from the American Academy of Pediatrics Resident Research Grant; the National Center for Advancing Translational Sciences of the National Institutes of Health (Award Number 5UL1TR001425) and the Cincinnati Children’s Hospital Medical Center Division of Critical Care Medicine.
J.M.K. reports financial support to the institution [Cincinnati Children’s Hospital Medical Center (CCHMC)] for work on a DSMB of a clinical trial (Eli Lilly) not related in any way to the work in the article. H.R.W. and the institution, CCHMC, hold patents for sepsis-related biomarkers. All remaining authors report no conflict of interest.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for Correspondence: Sonya C. Tang Girdwood, MD, PhD, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, MLC 9016, Cincinnati, OH. E-mail: firstname.lastname@example.org.